Exhibit 99.1
November 14, 2008 — Frequently Asked Questions and Answers — (FAQs) | ||
From time to time, Investor Relations will provide FAQs on various topics of interest. The following is a recent FAQ. | ||
Q | What are the IMS prescription volumes for VYTORIN and ZETIA? | |
A | U.S. Total Prescription Volume (000’s) |
Jan. | Feb. | March | April | May | June | |||||||||||||||||||
2008 | 2008 | 2008 | 2008 | 2008 | 2008 | |||||||||||||||||||
Cholesterol Management Market | 20,519 | 19,042 | 19,788 | 19,645 | 19,910 | 19,403 | ||||||||||||||||||
Total Merck/Schering-Plough Franchise | 3,226 | 2,790 | 2,820 | 2,507 | 2,479 | 2,351 | ||||||||||||||||||
VYTORIN | 1,851 | 1,607 | 1,619 | 1,428 | 1,412 | 1,330 | ||||||||||||||||||
ZETIA | 1,375 | 1,183 | 1,201 | 1,079 | 1,067 | 1,022 |
July | Aug. | Sept. | Oct. | |||||||||||||
2008 | 2008 | 2008 | 2008 | |||||||||||||
Cholesterol Management Market | 20,292 | 19,666 | 19,923 | 20,640 | ||||||||||||
Total Merck/Schering-Plough Franchise | 2,376 | 2,233 | 2,171 | 2,186 | ||||||||||||
VYTORIN | 1,339 | 1,249 | 1,202 | 1,207 | ||||||||||||
ZETIA | 1,038 | 984 | 969 | 978 |
Source: IMS’National Prescription Audit Plus (NPA+)as of November 12, 2008 which includes routine refinements by IMS to previously published data. | ||
DISCLOSURE NOTICE: The information in the frequently asked questions included in this FAQ, and in other written and oral statements about Schering-Plough and its business made by Schering-Plough or its officers from time to time, includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to prescription trends for VYTORIN and ZETIA. | ||
Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough’s forward-looking statements, including market forces (such as customer buying patterns); economic factors; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the timing and outcomes of the regulatory process; the timing and outcomes of clinical trials; and prescriber, patient and media reaction to data obtained from post-marketing clinical trials, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part II, Item 1A. “Risk Factors” in the third quarter 2008 10-Q, filed October 29, 2008. |